CCO Treatment Updates
Refining Antiretroviral Regimens: Improving Tolerability and Convenience for Virologically Suppressed HIV-Infected Patients
Virtual Presentations
21st Century Therapy: Advances in Antiretroviral Options
|
Program Director: Anton L. Pozniak, MD, FRCP
|
|
Kathleen E. Squires, MD, discusses 21st Century advances in antiretroviral development that include reformulations, coformulations, and agents that target new steps in the HIV infection cycle.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List several ways that HIV drugs have evolved
- Discuss clinical trial data that support the use of current fixed-dose coformulated drugs
- Review data from trials of investigational drugs that target new points in the HIV infection cycle
|
CCO Slideset – 21st Century Therapy: Advances in Antiretroviral Options
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 569 KB
|
Modifying Antiretroviral Therapy to Improve Convenience in Patients With Virologic Suppression
|
Program Director: Anton L. Pozniak, MD, FRCP
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses the clinical trial data evaluating switching regimens in patients with virologic suppression who are at risk for long-term adverse events.
Learning Objectives
Upon completion of this activity, participants should be able to:
- List the various possible rationales for modifying antiretroviral therapy in patients with virologic suppression
- Discuss antiretroviral switch strategies designed to improve the convenience of a suppressive regimen
- Review data from trials that have involved changes in antiretroviral therapy designed to prevent the development of adverse effects or to ameliorate toxicities already present
|
CCO Slideset – Modifying Antiretroviral Therapy to Improve Convenience in Patients With Virologic Suppression
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 853 KB
|
Should We Embrace Proactive Therapy Switches in Patients Who Are Tolerating Their Current Regimen, Based on Concerns About Potential Long-Term Toxicity? Pro and Con Arguments
|
Program Director: Anton L. Pozniak, MD, FRCP
 
- Jens D. Lundgren, MD, DMSc
- Benjamin Young, MD, PhD
|
|
|
Jens D. Lundgren, MD, and Benjamin Young, MD, PhD, debate the rationale for switching a patient’s current regimen based on avoiding potential long-term toxicities.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss reasons for switching antiretroviral regimens in patients with virologic suppression
- Define relative vs absolute risk as it relates to strategies for antiretroviral management of HIV-infected patients
- List potential reasons for suggesting a switch of antiretroviral regimen
|
CCO Slideset – Debate: Should We Embrace Proactive Therapy Switches in Patients Who Are Tolerating Their Current Regimen, Based on Concerns About Potential Long-term Toxicity?
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 246 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|